Back to Research Home
KRROKorro Bio, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations
$11.98−0.58%
As of 23 Oct 2026Mkt cap —
Stage 13
WAIT
Fundamentals
—/75
Technical
7.6/15
Independent
—/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- +25.2%
- 3M
- +11.8%
- 6M
- −7.1%
- 1Y
- −70.5%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- —
- FCF margin
- -1237.2%
- Current ratio
- 6.9x
Growth
- Revenue growth
- +181.5%Latest FY YoY
- Revenue CAGR
- −17.9%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +147.9%3Y annualised
- Net debt
- $22M
Annual trend
- CAGR 2021–2025
- −17.9%
- Latest · 2025
- $0B
- YoY
- +181.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-12
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded